<DOC>
	<DOCNO>NCT00694980</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study approximately 70 patient ulcerative colitis .</brief_summary>
	<brief_title>A Study Assess Safety , Pharmacokinetics , Pharmacodynamics , Immunogenicity rhuMAb Beta7 Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Able willing provide write informed consent 1870 year age Males females reproductive potential : Willing use reliable method contraception Diagnosis ulcerative colitis Eligible receive biologic therapy Disease duration &gt; =12 week Requirement hospitalization due severity ulcerative colitis Moderate severe anemia Any manifestation ulcerative colitis condition likely require , investigator 's judgment , treatment &gt; 20 mg/day prednisone , prednisone equivalent , course study Pregnant lactate Lack peripheral venous access Inability comply study protocol History presence contraindicate disease Congenital immune deficiency Active prior infection HIV hepatitis B C History severe systemic bacterial , fungal , viral , parasitic infection History opportunistic infection within 12 week prior initiation study treatment Received live attenuate vaccine within 4 week prior screen Hospitalized within 4 week prior screen Received contraindicated therapy within 12 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>UC</keyword>
	<keyword>Ulcerative Colitis</keyword>
</DOC>